Full Press Release Details
| Dr. Reddy's Laboratories Ltd. | |
| 8-2-337, Road No. 3, Banjara Hills, | |
| Hyderabad - 500 034, Telangana, | |
| India. | |
| CIN : L85195TG1984PLC004507 | |
| Tel :+91 40 4900 2900 | |
| Fax :+91 40 4900 2999 | |
| Email : mail@drreddys.com | |
| www.drreddys.com |
| January 24, 2018 | ||
| Corporate Relationship Department | National Stock Exchange of India Ltd. | |
| BSE Limited | "Exchange Plaza" | |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), | |
| Mumbai - 400 001 | Mumbai - 400 051 | |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ | |
| 22722037 / 22722039 | 26598238 | |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
This has reference to our intimation dated
August 10, 2017 with regard to communication received by betapharm Arzneimittel GmbH, Germany (our wholly-owned subsidiary) from
the Regulatory Authority of Germany (Regierung von Oberbayern).
There has been a re-inspection carried out
by the German Regulator at the Company's Formulations Manufacturing Unit 2 plant in Bachupally, Hyderabad last week. Following
the re-inspection, betapharm has now received a communication from the Regulator that the current status of EU GMP non-compliance
(from August 8, 2017) is to be withdrawn from Government of Upper Bavaria.
The plant can now restart despatch of approved
products to the European Union.
This is for your information and record.
| /s/ Sandeep Poddar | |
| Sandeep Poddar | |
| Company Secretary |
CC:- New York Stock Exchange Inc.(Stock Code :RDY)